Evidence map›Paper›PMID 39148855›Full record

ArticlemedRxiv : the preprint server for health sciences2024

A foundation model for clinician-centered drug repurposing.

Kexin Huang, Payal Chandak, Qianwen Wang, Shreyas Havaldar, Akhil Vaid, Jure Leskovec, Girish Nadkarni, Benjamin S Glicksberg, Nils Gehlenborg, Marinka Zitnik

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Kexin HuangDepartment of Biomedical Informatics, Harvard Medical School, Boston, MA 02115.ORCID 0000-0001-6693-8390
Payal ChandakHarvard-MIT Program in Health Sciences and Technology, Cambridge, MA 02139.ORCID 0000-0003-1097-803X
Qianwen WangDepartment of Biomedical Informatics, Harvard Medical School, Boston, MA 02115.ORCID 0000-0003-1728-4102
Shreyas HavaldarHasso Plattner Institute for Digital Health, Icahn School of Medicine at Mount Sinai, NY 10029.ORCID 0000-0001-8783-7791
Akhil VaidHasso Plattner Institute for Digital Health, Icahn School of Medicine at Mount Sinai, NY 10029.ORCID 0000-0002-3343-744X
Jure LeskovecDepartment of Computer Science, Stanford University, Stanford, CA 94305.ORCID 0000-0002-5411-923X
Girish NadkarniCharles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, NY 10029.ORCID 0000-0001-6319-4314
Benjamin S GlicksbergHasso Plattner Institute for Digital Health, Icahn School of Medicine at Mount Sinai, NY 10029.ORCID 0000-0003-4515-8090
Nils GehlenborgDepartment of Biomedical Informatics, Harvard Medical School, Boston, MA 02115.ORCID 0000-0003-0327-8297
Marinka ZitnikDepartment of Biomedical Informatics, Harvard Medical School, Boston, MA 02115.ORCID 0000-0001-8530-7228

Funding

Measuring Neonatal RegionalizationR01HD108794 · NICHD · STANFORD UNIVERSITY · PI Jochen Profit, JEANNETTE A ROGOWSKI · 2023 to 2026
$2.8M
NICHD NIH HHS R01 HD108794
6 · The paper itself

Abstract

Drug repurposing - identifying new therapeutic uses for approved drugs - is often serendipitous and opportunistic, expanding the use of drugs for new diseases. The clinical utility of drug repurposing AI models remains limited because the models focus narrowly on diseases for which some drugs already exist. Here, we introduce TXGNN, a graph foundation model for zero-shot drug repurposing, identifying therapeutic candidates even for diseases with limited treatment options or no existing drugs. Trained on a medical knowledge graph, TXGNN utilizes a graph neural network and metric-learning module to rank drugs as potential indications and contraindications across 17,080 diseases. When benchmarked against eight methods, TXGNN improves prediction accuracy for indications by 49.2% and contraindications by 35.1% under stringent zero-shot evaluation. To facilitate model interpretation, TXGNN's Explainer module offers transparent insights into multi-hop medical knowledge paths that form TXGNN's predictive rationales. Human evaluation of TXGNN's Explainer showed that TXGNN's predictions and explanations perform encouragingly on multiple axes of performance beyond accuracy. Many of TxGNN's novel predictions align with off-label prescriptions clinicians make in a large healthcare system. TXGNN's drug repurposing predictions are accurate, consistent with off-label drug use, and can be investigated by human experts through multi-hop interpretable rationales.

Identifiers

PMID39148855
PMCPMC11326339

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.